surmount-1 tirzepatide trial obesity without diabetes vs semaglutide: A new battle in treatment Tirzepatide Tops Semaglutide for Weight

Are the medications you prescribe FDA-approved

By targeting this pathway, AOD 9604 has been shown to help maintain lean mass in certain models, without exhibiting the growth-promoting effects of intact HGH

1,2 The results are consistent with actions taken by the European Medicines Agency (EMA) in June 2025, when the agency classified NAION as a very rare side effect of semaglutide and recommended product labeling updates. Epidemiologic data reviewed by the EMA suggested an approximately twofold increased risk in adults with type 2 diabetes, corresponding to roughly one additional case per 10,000 person-years of treatment. The agency advised that patients with sudden vision loss or rapidly worsening eyesight seek immediate medical attention and discontinue treatment if NAION is confirmed. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation Study strengths Methodologically, the VA study offers several strengths: The analysis leveraged the largest integrated health care system in the United States, with medication exposure confirmed through pharmacy dispensing records rather than prescription data alone

They can improve symptoms such as numbness and tingling, weakness, difficulty walking and memory trouble, as well as reduce anemia and fatigue

Its robust GH-releasing activity is well-documented across decades of research, and its preclinical cardioprotective profile remains one of the most intriguing areas of ongoing investigation

Zinc is another nutrient thats key for skin elasticity